AI/ ML will revolutionize medicine by making diagnosis and treatment more accessible and more effective.
FDA has regulated medical software by means of regulations and guidance for years, however, AI/ML programs fall outside the scope of these regulations and guidances.
This happens because FDA approves the final, validated version of the software. The point of AI/ML is to learn and update following deployment to improve performance. Thus the field version of the software is no longer the validated approved version.
We will discuss the current regulatory requirements, how they don’t control AI/ML adequately, and approaches FDA is considering for regulation in the near future. Your development program should conform to these concepts now because, with some modifications, they will probably become regulations.
Following a discussion of possible future regulations, we will discuss, based on recently approved De Novo applications, how to get your AI/ML program approved now. Necessary submission documentation will be explained.
This webinar is not a programming course but will explain the present and future regulatory requirements for AI/ML.
WHY SHOULD YOU ATTEND?
- It is not clear how to get AI/ML programs approved. The current regulatory requirements don’t control AI/ML adequately.
- We will discuss the approaches FDA is considering for regulation in the near future and how to get your AI/ML program approved by FDA now.
- Necessary submission documentation will be explained Attendees will receive a multipage outline and checklist.
AREA COVERED
- Total product life cycle approach to AI/ ML design
- Application of FDA software Pre Cert program to AI/ ML
- FDA discussion paper on AI/ML
- Database management
- QC of datasets
- Algorithm updating
- Reference standard development
- Standalone performance testing
- Clinical performance testing
- Data Enrichment
- Emphasis on "explainability"
- Additional labeling requirements
- Cybersecurity
WHO WILL BENEFIT?
Managers, Supervisors, Directors, and Vice-Presidents in the areas of:
- Software Engineers
- Engineers
- Regulatory Personnel
- Quality Assurance Personnel
- Marketing
- Management
- It is not clear how to get AI/ML programs approved. The current regulatory requirements don’t control AI/ML adequately.
- We will discuss the approaches FDA is considering for regulation in the near future and how to get your AI/ML program approved by FDA now.
- Necessary submission documentation will be explained Attendees will receive a multipage outline and checklist.
- Total product life cycle approach to AI/ ML design
- Application of FDA software Pre Cert program to AI/ ML
- FDA discussion paper on AI/ML
- Database management
- QC of datasets
- Algorithm updating
- Reference standard development
- Standalone performance testing
- Clinical performance testing
- Data Enrichment
- Emphasis on "explainability"
- Additional labeling requirements
- Cybersecurity
Managers, Supervisors, Directors, and Vice-Presidents in the areas of:
- Software Engineers
- Engineers
- Regulatory Personnel
- Quality Assurance Personnel
- Marketing
- Management
Speaker Profile
Edwin Waldbusser, is a consultant retired from industry after 20 years in management of development of medical devices (5 patents). He has been consulting in the areas of design control, risk analysis and software validation for the past 8 years. Mr. Waldbusser has a BS in Mechanical Engineering and an MBA. He is a Lloyds of London certified ISO 9000 Lead Auditor and a member of the Thomson Reuters Expert Witness network.
Upcoming Webinars
OSHA Requirements for Supervisors, Project Leaders & HR - W…
California Meal and Rest Breaks: What You Don't Know Can Co…
Treasury Risk Management, Funding, Liquidity, Interest Rate…
Future-Proof Your Workforce: Mastering Succession Planning …
FFIEC BSA/AML Examination Manual: What Compliance Officers …
HIPAA Bootcamp for Health Care Providers, Professionals, an…
Improving Employee Engagement & Retention Through Stay Inte…
Essential Job Functions According to the American with Disa…
Conquer Toxic People - Learn To Protect Yourself And Get Yo…
Dealing With Difficult People In Life & Work
Updated Metro 2®, e-OSCAR and the New Tougher FCRA/CFPB Com…
Introduction to Generative AI for Accountants
Surviving and Thriving Organizational Change and Loss: The …
How to Write Effective Audit Observations: The Principles f…
Impact Assessment and Risk Management for Change Control
3-Hour Virtual Seminar on Excel Deep Dive: Advanced Tips & …
Coming Soon - New Minimum Salary Levels for Exempt Employee…
Marijuana: Compliance and Safety in the Workplace
Stressed Out: How to Handle Conflict, Difficult People and …
FDA Regulation of Artificial Intelligence/ Machine Learning
Data Integrity: Compliance with 21 CFR Part 11, SaaS-Cloud,…
How to Handle Workplace Conversations Around Politics and R…
2025 Top Employment Regulations That Will Impact Employers!
How to Give Corrective Feedback: The CARE Model - Eliminati…
Why EBITDA Doesn't Spell Cash Flow and What Does
SOPs - How to Write Them to Satisfy those Inspectors
Documenting Misconduct that Will Stand Up in Court
Human Error Reduction Techniques for Floor Supervisors
With Mandatory Paid Leave Gaining Ground Is It Time To Do A…
Marketing to Medicare or Medicaid Beneficiaries - What You …
Trial Master File (TMF)/eTMF, & FDAs Draft Guidance for Ele…
Tattoos, hijabs, piercings, and pink hair: The challenges …
Project Management for Non-Project Managers - How to commun…
Unlock Employee Loyalty: Stay Interviews Will Keep Them Eng…
Sunshine Act Reporting - Clarification for Clinical Research
Female to Female Hostility @Workplace: All you Need to Know
Onboarding is NOT Orientation - How to Improve the New Empl…
Managing Toxic & Other Employees Who Have Attitude Issues
Building GMP Excellence: A Guide to Implementing Compliant …
Excel Power Skills: Master Functions, Formulas, and Macros …